OncLive TV

Dr. Davies on Future Research Directions With Isatuximab in Multiple Myeloma

June 16th 2021

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.

Dr. Martin on the Rationale to Evaluate Real-World Outcomes in MCL

June 16th 2021

Peter Martin, MD, discusses the rationale to evaluate real-world outcomes in mantle cell lymphoma.

Dr. Byrd on the Clinical Implications of the ELEVATE-RR Trial in CLL

June 16th 2021

John C. Byrd, MD, discusses the clinical implications of the phase 3 ELEVATE-RR trial in chronic lymphocytic leukemia.

Dr. Charlton on the Interaction Between Liver Disease and HCC

June 16th 2021

Michael R. Charlton, MD, MBBS, discusses the interaction between liver disease and hepatocellular carcinoma.

Dr. Jones on the Importance of Testing for Microsatellite Instability in CRC

June 15th 2021

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

Dr. Wei on the Potential Implications of the CompassHER2 RD Trial in HER2+ Breast Cancer

June 15th 2021

Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

Dr. Choudhury on Emerging Treatment Strategies in mCRPC

June 15th 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Dr. Strickler on Selecting Between TAS-102 and Regorafenib in CRC

June 14th 2021

John H. Strickler, MD, discusses factors to consider when selecting between trifluridine/tipiracil and regorafenib for the treatment of patients with colorectal cancer.

Dr. Atkins on Safety Considerations For Neoadjuvant Approaches in Gastric Cancer

June 14th 2021

Katelyn M. Atkins, MD, PhD, discusses safety considerations for neoadjuvant approaches in patients with gastric cancer.

Dr. Ghia on the Efficacy of Ibrutinib/Venetoclax in CLL

June 12th 2021

Paolo Ghia, MD, PhD, discusses results seen with the combination of ibrutinib and venetoclax as a first-line treatment for patients with chronic lymphocytic leukemia.